重组人脑利钠肽联合芪苈强心胶囊治疗慢性心衰

Efficacy analysis of recombinant human brain natriuretic peptide combined with Qiliqiangxin capsule in the treatment of chronic heart failure

目的研究重组人脑利钠肽联合芪苈强心胶囊治疗慢性心力衰竭的临床疗效。方法选取48例慢性心衰的患者,随机分为对照组(24例)和观察组(24例),两组患者均给与常规治疗以及芪苈强心胶囊治疗,观察组加用重组人脑利钠肽,所有患者治疗两周后观察其临床疗效,比较两组患者的SV、LVEF、LVEDV、NT-proBNP的变化以及半年后随访结果。结果观察组的总有效率为70.83%,对照组的总有效率为95.83%,观察组治疗效果明显高于对照组(P=0.001),治疗后,观察组的SV、LVEF均高于对照组((P<0.05)),LVEDV、NT-proBNP低于对照组(P<0.05);观察组治疗后半年的再入院率低于对照组(P<0.05),死亡率无明显差异。结论重组人脑利钠肽联合芪苈强心胶囊治疗慢性心衰的临床疗效显著,并能降低患者再入院率,可有效改善患者预后。

To study the clinical efficacy of recombinant human brain natriuretic peptide combined with Qiliqiangxin capsules in the treatment of chronic heart failure.Methods 48 patients with chronic heart failure from August 2019 to October 2020 were selected and randomly divided into a control group(24 cases)and the observation group(24 cases).Both groups were given conventional treatment and Qiliqiangxin capsule treatment.The observation group was treated with recombinant human brain natriuretic peptide.All patients were treated for two weeks to observe their clinical efficacy and compare the changes of SV,LVEF,LVEDV,NT-proBNP of the two groups of patients and the follow-up after half a year.Results The total effective rate of the observation group was 70.83%,and the total effective rate of the control group was 95.83%.The treatment effect of the observation group was significantly higher than the control group(P=0.001).After treatment,SV and LVEF of the observation group were higher than those of the control group(P<0.05),and LVEDV and NT-proBNP were lower than those of the control group(P<0.05);the readmission rate was lower than that of the control group(P<0.05),and there was no significant difference in mortality.Conclusion The clinical effect of recombinant human brain natriuretic peptide combined with Qiliqiangxin capsule in the treatment of chronic heart failure is significant,and it can reduce the readmission rate of patients.Effectively improve the prognosis of patients.